Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 10/20 | 0.48 |
| ▸ | OXTR | P30559 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202917 | 1.00 | AVPR2 (0.48) | AVPR2OXTRALDH1A1EPHX2NR1H4 | |
| SCHEMBL6203853 | 0.93 | AVPR2 (0.50) | AVPR2OXTRALDH1A1EPHX2NR1H4 | |
| SCHEMBL6203570 | 0.82 | AVPR2 (0.52) | AVPR2OXTRALDH1A1EPHX2CYP2C9 | |
| SCHEMBL6199880 | 0.82 | AVPR2 (0.52) | AVPR2OXTRALDH1A1EPHX2CYP2C9 | |
| SCHEMBL6202640 | 0.76 | AVPR2 (0.81) | AVPR2OXTR | |
| SCHEMBL6203139 | 0.76 | AVPR2 (0.81) | AVPR2OXTR | |
| SCHEMBL6202921 | 0.72 | EPHX2 (0.37) | ALDH1A1EPHX2NR1H4CYP2C9CYP2J2 | |
| SCHEMBL12231188 | 0.70 | EPHX2 (0.50) | ALDH1A1EPHX2NR1H4 | |
| SCHEMBL239963 | 0.67 | UCHL1 (0.49) | — | |
| SCHEMBL5480506 | 0.67 | UCHL1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1399436-A2 | OXYTOCIN AGONISTS | Ferring BV (NL) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003000692-A2 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | AVPR2 10/4885OXTR 1/4885ALDH1A1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.